Rockefeller Capital Management L.P. Has $3.63 Million Stock Holdings in Labcorp Holdings Inc. $LH

Rockefeller Capital Management L.P. decreased its stake in shares of Labcorp Holdings Inc. (NYSE:LH) by 11.7% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 14,472 shares of the medical research company’s stock after selling 1,916 shares during the quarter. Rockefeller Capital Management L.P.’s holdings in Labcorp were worth $3,631,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Fund Advisors of America Inc FL acquired a new stake in Labcorp during the 4th quarter worth approximately $286,000. World Investment Advisors grew its holdings in Labcorp by 23.2% in the 4th quarter. World Investment Advisors now owns 1,724 shares of the medical research company’s stock valued at $433,000 after buying an additional 325 shares in the last quarter. Corient Private Wealth LLC grew its holdings in Labcorp by 14.9% in the 4th quarter. Corient Private Wealth LLC now owns 31,018 shares of the medical research company’s stock valued at $7,786,000 after buying an additional 4,031 shares in the last quarter. Hsbc Holdings PLC increased its position in Labcorp by 33.8% during the 4th quarter. Hsbc Holdings PLC now owns 189,502 shares of the medical research company’s stock worth $47,608,000 after buying an additional 47,850 shares during the period. Finally, SHP Wealth Management acquired a new stake in shares of Labcorp during the fourth quarter worth $40,000. Institutional investors own 95.94% of the company’s stock.

Labcorp Price Performance

Shares of NYSE LH opened at $272.09 on Friday. The business has a fifty day moving average price of $260.97 and a two-hundred day moving average price of $265.49. The stock has a market capitalization of $22.31 billion, a PE ratio of 24.10, a P/E/G ratio of 1.90 and a beta of 0.90. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. Labcorp Holdings Inc. has a fifty-two week low of $241.81 and a fifty-two week high of $293.72.

Labcorp (NYSE:LH) last released its earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same period in the prior year, the firm posted $3.84 EPS. Labcorp’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities analysts predict that Labcorp Holdings Inc. will post 18 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, June 11th. Shareholders of record on Friday, May 29th were paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date was Friday, May 29th. Labcorp’s dividend payout ratio is presently 25.51%.

Insider Transactions at Labcorp

In other Labcorp news, CEO Adam H. Schechter sold 5,903 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the transaction, the chief executive officer directly owned 107,234 shares of the company’s stock, valued at $27,291,053. This trade represents a 5.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Kathryn W. Kyle sold 762 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $263.89, for a total transaction of $201,084.18. Following the completion of the transaction, the executive vice president owned 3,813 shares of the company’s stock, valued at $1,006,212.57. The trade was a 16.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Robert W. Baird set a $334.00 price target on shares of Labcorp in a research note on Friday, May 1st. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Labcorp from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Evercore restated an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $308.00.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.